We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Executive says patients on other medications will not be able to take competing antiviral treatment
Experts advising FDA recommend treatment for high-risk patients amid fears over Omicron variant
Full analysis of trial results shows molnupiravir had a risk reduction of 30%
New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?
First authorisation for antiviral drug that halves risk of hospitalisation or death
Move contrasts with mRNA makers Pfizer and Moderna, which have rejected sharing vaccine technology
Molnupiravir has limitations but drugmakers should be able to build on it to create other treatments
Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people
Investors fret over how company will fare when Keytruda loses exclusivity
US pharma group seeks authorisation for first drug of its kind after ‘remarkable’ clinical trial
Acquisition will expand US pharmaceutical company’s pipeline of cardiovascular treatments
Lynparza shown to reduce recurrence rates, while Novartis to unveil new type of radiotherapy
New vaccine producers and mRNA technology are shaking up the market
White House announces accelerated timeline after brokering production deal between J&J and Merck
Approach seeks to cut years off traditional licensing process for treatments
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
Executive vice-president Robert Davis will take helm at US drugmaker
After lacklustre results, company says it will shift focus to potential drugs to treat the disease
US pharma group says Britain is ‘world leader’ in developing science
Wayne Holman and his wife Wendy are betting they can change the course of the pandemic
Pharma group’s publicity-shy chief has made a remarkable intervention over George Floyd’s killing
Pill that aims to force virus to mutate to self-destruction set for extensive clinical trials in US and UK
Ken Frazier calls 12 to 18-month targets ‘very aggressive’ as he announces biotech acquisition
On paper, the spin-off looks promising, but there is some pause for thought
New company with $6.5bn in revenue will include women’s health unit and legacy brands
International Edition
